1. Carluccio E; Dini FL; Bitto R; Ciccarelli M; Correale M; D'Agostino A; Dattilo G; Ferretti M; Grelli A; Guida S; Jacoangeli F; Lupi L; Luschi L; Masarone D; Mercurio V; Pacileo G; Pugliese NR; Rispoli A; Scelsi L; Tocchetti CG; Brunetti ND; Palazzuoli A; Piepoli M; Nodari S; Ambrosio G; Working
Group on Heart Failure of the Italian Society of Cardiology. Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure
with reduced ejection fraction: An echocardiographic study. Int J Cardiol 2022,S0167-5273(22)00004-3
2. Ameri P; De Marzo V; Zoccai GB; Tricarico L; Correale M; Brunetti ND; Canepa M; De Ferrari GM; Castagno D; Porto I; Efficacy of new medical therapies
in patients with heart failure, reduced ejection fraction and chronic kidney disease already receiving neurohormonal inhibitors: a network metaanalysis. Eur Heart J Cardiovasc Pharmacother 2021,pvab088
3. Lacedonia D.; Correale M.; Tricarico L.; Scioscia G.; Stornelli S.R.; Simone F.; Casparrini M.; Brunetti N.D.; Foschino B.M.P.; Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone. Intern Emerg Med 2021,1-8
4. Correale M.; Mazzeo P.; Mallardi A.; Leopizzi A.; Tricarico L.; Fortunato M.; Magnesa M.; Tucci S.; Maiellaro P.; Pastore G.; Lamacchia O.; Iacoviello M.; Di Biase M.; Brunetti N.D.; Switch to SGLT2 inhibitors and improved endothelial function in diabetic patients with chronic heart failure. Cardiovasc Drugs Ther 2021,1-8
5. Correale M.; Mazzeo P.; Magnesa M.; Fortunato M.; Tricarico L.; Leopizzi A.; Mallardi A.; Mennella R.; Tucci S.; Brunetti N.D.; Predictors of right ventricular function improvement with sacubitril/valsartan in a real-life population of patients with chronic heart failure. Clin Physiol Funct Imaging 2021,41(6),505-513